Logo for University of Iowa Health Care This logo represents the University of Iowa Health Care

Jeanine Schibler

Mentor: Apollina Goel, Ph.D.
Lab Room: 4234 MERF
Lab Phone: 319-335-8864

Characterization of myeloma cancer stem cells

In the Goel lab, our research is focused on designing mechanism-based therapies for B-cell malignancies including multiple myeloma (MM). MM is a plasma cell cancer that has a high rate of relapse and drug resistance after treatment with frontline chemotherapeutics. One hypothesis for this outcome is the existence of a population of myeloma cancer stem cells, which have increased drug resistance compared to the remainder of the tumor cell population and are able to repopulate the tumor after chemotherapy. In my research project, I am studying how alterations in redox homeostasis and microRNA expression patterns can be used to uncover mechanisms to target the myeloma cancer stem cell population. I will be extending the cell culture findings to in vivo studies by utilizing the 5TGM1 murine myeloma model to evaluate new chemotherapy combinations for eliminating the myeloma cancer stem cells.

Brown CO, Schibler J, Fitzgerald MP, Singh N, Salem K, Zhan F, Goel A. Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma. Leuk Res. 2013 Mar 25. doi:pii:S0145-2126(13)00079-9. 10.1016/j.leukres.2013.03.004. [Epub ahead of print] PubMed PMID: 23537707.

Salem K, Brown CO, Schibler J, Goel A. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. Exp Hematol. 2013 Feb;41(2):209-18. doi: 10.1016/j.exphem.2012.10.002. Epub 2012 Oct 11. PubMed PMID: 23063726; PubMed Central PMCID: PMC3565034.